Testing two medicines before surgery for HER2-positive breast cancer
Part of Cancer, Skin clinical trials.
This Phase 2 trial compares nab-PH plus pyrrolitinib versus TCbHP as treatment given before breast surgery. It aims to see which option works better and is safe for people with HER2-positive invasive breast cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 to 65, and your daily activity level is good (ECOG 0–1).
- Your breast cancer is HER2-positive, confirmed by pathology testing (tumor shows HER2 3+ on staining or is HER2-positive on FISH testing).
- Your cancer is not spread to distant organs (no stage IV/metastatic breast cancer).
- Your tumor is at an operable stage: T2 to T4d, or T1c with cancer in the underarm lymph node (axillary LN+).
- You have test results that show you can safely take chemotherapy (blood counts, liver, kidneys meet study cutoffs).
- Your heart ultrasound shows good pumping function (LVEF at least 55%), and you do not have certain serious heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two different drug combinations given before surgery to shrink HER2-positive breast cancer tumors. The goal is to see which combination works better and has fewer side effects.
This trial compares two combinations of drugs given before surgery to shrink HER2-positive breast cancer. One uses a new experimental drug (TQB2102) and the other uses standard treatments. The goal is to see which works better at reducing the cancer before surgery.
This trial tests a combination of targeted therapies and chemotherapy given before surgery for women with a specific type of breast cancer that is both ER-positive and HER2-positive. The goal is to see if this treatment can shrink tumors and improve outcomes.
This trial tests a combination of two targeted drugs (pyrotinib and trastuzumab) plus chemotherapy (capecitabine) before surgery for women with early-stage HER2-positive breast cancer. The goal is to shrink the tumor and improve treatment outcomes.
This study tests a personalized treatment approach for HER2-positive breast cancer. It uses regular monitoring of your tumor to adjust the treatment before surgery, aiming to improve results. It might help you by tailoring therapy to your cancer's response.
This study tests two chemotherapy drugs, lobaplatin and carboplatin, given before surgery for HER2 positive breast cancer. The goal is to see if they are safe and help shrink the tumor before it is removed.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.